Suppression of SOCS3 in macrophages prevents cancer metastasis by modifying macrophage phase and MCP2/CCL8 induction

Cancer Letters

Volumn 308, Issue 2, 2011, Pages 172-180

  Hiwatashi, Kiyokazu ^a,b   Tamiya, Taiga ^a,b   Hasegawa, Eiichi ^a,b   Fukaya, Tomohiro ^a,b   Hashimoto, Masayuki ^a,b   Kakoi, Kyosuke ^a,b   Kashiwagi, Ikko ^a,b   Kimura, Akihiro ^a,b   Inoue, Naoko ^a,b   Morita, Rimpei ^a,b   Yasukawa, Hideo ^c   Yoshimura, Akihiko ^a,b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytokine; MCP2 CCL8; SOCS3; STAT3; Tumor associated macrophage

Indexed keywords

INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 2; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CANCER TRANSPLANTATION; CARCINOGENESIS; CELL STRAIN B16F10; CONTROLLED STUDY; IN VITRO STUDY; KNOCKOUT MOUSE; LIVER METASTASIS; LUNG METASTASIS; MACROPHAGE; MELANOMA CELL; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; TUMOR VOLUME; WILD TYPE;

ANIMALS; BLOTTING, WESTERN; CHEMOKINE CCL8; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; NEOPLASM METASTASIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

MUS;

EID: 79959567446     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.04.024     Document Type: Article

References (39)

1. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
2. Yoshimura A. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci. 2006, 97:439-447.
3. Hashimoto M., Ayada T., Kinjyo I., Hiwatashi K., Yoshida H., Okada Y., Kobayashi T., Yoshimura A. Silencing of SOCS1 in macrophages suppresses tumor development by enhancing antitumor inflammation. Cancer Sci. 2009, 100:730-736.
4. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.
5. Shouda T., Hiraoka K., Komiya S., Hamada T., Zenmyo M., Iwasaki H., Isayama T., Fukushima N., Nagata K., Yoshimura A. Suppression of IL-6 production and proliferation by blocking STAT3 activation in malignant soft tissue tumor cells. Cancer Lett. 2006, 231:176-184.
6. Ogata H., Chinen T., Yoshida T., Kinjyo I., Takaesu G., Shiraishi H., Iida M., Kobayashi T., Yoshimura A. Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-beta1 production. Oncogene 2006, 25:2520-2530.
7. Ogata H., Kobayashi T., Chinen T., Takaki H., Sanada T., Minoda Y., Koga K., Takaesu G., Maehara Y., Iida M., Yoshimura A. Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology 2006, 131:179-193.
8. Riehle K.J., Campbell J.S., McMahan R.S., Johnson M.M., Beyer R.P., Bammler T.K., Fausto N. Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3. J. Exp. Med. 2008, 205:91-103.
9. Niwa Y., Kanda H., Shikauchi Y., Saiura A., Matsubara K., Kitagawa T., Yamamoto J., Kubo T., Yoshikawa H. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 2005, 24:6406-6417.
10. Yoshimura A., Naka T., Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 2007, 7:454-465.
11. Kubo M., Hanada T., Yoshimura A. Suppressors of cytokine signaling and immunity. Nat. Immunol. 2003, 4:1169-1176.
12. Stoiber D., Kovarik P., Cohney S., Johnston J.A., Steinlein P., Decker T. Lipopolysaccharide induces in macrophages the synthesis of the suppressor of cytokine signaling 3 and suppresses signal transduction in response to the activating factor IFN-gamma. J. Immunol. 1999, 163:2640-2647.
13. Yasukawa H., Ohishi M., Mori H., Murakami M., Chinen T., Aki D., Hanada T., Takeda K., Akira S., Hoshijima M., Hirano T., Chien K.R., Yoshimura A. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat. Immunol. 2003, 4:551-556.
14. Sasaki A., Inagaki-Ohara K., Yoshida T., Yamanaka A., Sasaki M., Yasukawa H., Koromilas A.E., Yoshimura A. The N-terminal truncated isoform of SOCS3 translated from an alternative initiation AUG codon under stress conditions is stable due to the lack of a major ubiquitination site, Lys-6. J. Biol. Chem. 2003, 278:2432-2436.
15. Nicholson S.E., De Souza D., Fabri L.J., Corbin J., Willson T.A., Zhang J.G., Silva A., Asimakis M., Farley A., Nash A.D., Metcalf D., Hilton D.J., Nicola N.A., Baca M. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc. Natl. Acad. Sci. USA 2000, 97:6493-6498.
16. Takeda K., Clausen B.E., Kaisho T., Tsujimura T., Terada N., Forster I., Akira S. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 1999, 10:39-49.
17. Kortylewski M., Xin H., Kujawski M., Lee H., Liu Y., Harris T., Drake C., Pardoll D., Yu H. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009, 15:114-123.
18. Herrmann A., Kortylewski M., Kujawski M., Zhang C., Reckamp K., Armstrong B., Wang L., Kowolik C., Deng J., Figlin R., Yu H. Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res. 2010, 70:7455-7464.
19. Liu Y., Stewart K.N., Bishop E., Marek C.J., Kluth D.C., Rees A.J., Wilson H.M. Unique expression of suppressor of cytokine signaling 3 is essential for classical macrophage activation in rodents in vitro and in vivo. J. Immunol. 2008, 180:6270-6278.
20. Matsumura Y., Kobayashi T., Ichiyama K., Yoshida R., Hashimoto M., Takimoto T., Tanaka K., Chinen T., Shichita T., Wyss-Coray T., Sato K., Yoshimura A. Selective expansion of foxp3-positive regulatory T cells and immunosuppression by suppressors of cytokine signaling 3-deficient dendritic cells. J. Immunol. 2007, 179:2170-2179.
21. Van Damme J., Proost P., Lenaerts J.P., Opdenakker G. Structural and functional identification of two human, tumor-derived monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemokine family. J. Exp. Med. 1992, 176:59-65.
22. Uguccioni M., D'Apuzzo M., Loetscher M., Dewald B., Baggiolini M. Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes. Eur. J. Immunol. 1995, 25:64-68.
23. Loetscher P., Seitz M., Clark-Lewis I., Baggiolini M., Moser B. Monocyte chemotactic proteins MCP-1, MCP-2, and MCP-3 are major attractants for human CD4+ and CD8+ T lymphocytes. Faseb. J. 1994, 8:1055-1060.
24. Taub D.D., Proost P., Murphy W.J., Anver M., Longo D.L., van Damme J., Oppenheim J.J. Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J. Clin. Invest. 1995, 95:1370-1376.
25. Hiratsuka S., Nakamura K., Iwai S., Murakami M., Itoh T., Kijima H., Shipley J.M., Senior R.M., Shibuya M. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002, 2:289-300.
26. Hatfield P., Merrick A.E., West E., O'Donnell D., Selby P., Vile R., Melcher A.A. Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy. J. Immunother. 2008, 31:620-632.
27. Koga K., Takaesu G., Yoshida R., Nakaya M., Kobayashi T., Kinjyo I., Yoshimura A. Cyclic adenosine monophosphate suppresses the transcription of proinflammatory cytokines via the phosphorylated c-Fos protein. Immunity 2009, 30:372-383.
28. Torisu T., Sato N., Yoshiga D., Kobayashi T., Yoshioka T., Mori H., Iida M., Yoshimura A. The dual function of hepatic SOCS3 in insulin resistance in vivo. Genes Cells 2007, 12:143-154.
29. Taniguchi K., Ishizaki T., Ayada T., Sugiyama Y., Wakabayashi Y., Sekiya T., Nakagawa R., Yoshimura A. Sprouty4 deficiency potentiates Ras-independent angiogenic signals and tumor growth. Cancer Sci. 2009, 100:1648-1654.
30. Nonami A., Taketomi T., Kimura A., Saeki K., Takaki H., Sanada T., Taniguchi K., Harada M., Kato R., Yoshimura A. The Sprouty-related protein, Spred-1, localizes in a lipid raft/caveola and inhibits ERK activation in collaboration with caveolin-1. Genes Cells 2005, 10:887-895.
31. Miyoshi K., Wakioka T., Nishinakamura H., Kamio M., Yang L., Inoue M., Hasegawa M., Yonemitsu Y., Komiya S., Yoshimura A. The Sprouty-related protein, Spred, inhibits cell motility, metastasis, and Rho-mediated actin reorganization. Oncogene 2004, 23:5567-5576.
32. Piccinini A.M., Midwood K.S. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm. 2010, 2010.
33. Struyf S., Proost P., Vandercappellen J., Dempe S., Noyens B., Nelissen S., Gouwy M., Locati M., Opdenakker G., Dinsart C., Van Damme J. Synergistic up-regulation of MCP-2/CCL8 activity is counteracted by chemokine cleavage, limiting its inflammatory and anti-tumoral effects. Eur. J. Immunol. 2009, 39:843-857.
34. Colombo M.P., Mantovani A. Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion. Cancer Res. 2005, 65:9113-9116.
35. Ji Y., Zhang W. Th17 cells: positive or negative role in tumor?. Cancer Immunol. Immunother. 2010, 59:979-987.
36. Mantovani A., Dejana E. Cytokines as communication signals between leukocytes and endothelial cells. Immunol. Today 1989, 10:370-375.
37. Le Y., Zhu B.M., Harley B., Park S.Y., Kobayashi T., Manis J.P., Luo H.R., Yoshimura A., Hennighausen L., Silberstein L.E. SOCS3 protein developmentally regulates the chemokine receptor CXCR4-FAK signaling pathway during B lymphopoiesis. Immunity 2007, 27:811-823.
38. Hintzen C., Haan C., Tuckermann J.P., Heinrich P.C., Hermanns H.M. Oncostatin M-induced and constitutive activation of the JAK2/STAT5/CIS pathway suppresses CCL1, but not CCL7 and CCL8, chemokine expression. J. Immunol. 2008, 181:7341-7349.
39. Van Damme J., Struyf S., Opdenakker G. Chemokine-protease interactions in cancer. Semin. Cancer Biol. 2004, 14:201-208.